Study Finds Gemcitabine/Cisplatin Improved Outcome vs Fluorouracil/Cisplatin in Recurrent or Metastatic Nasopharyngeal Carcinoma

Key Points

  • Gemcitabine/cisplatin prolonged progression-free survival vs infusional fluorouracil/cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
  • Gemcitabine/cisplatin was associated with a better objective response rate and overall survival.

In a Chinese phase III trial reported in The Lancet, Zhang et al found that gemcitabine/cisplatin improved progression-free survival vs fluorouracil/cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.

Study Details

In the open-label trial, 362 patients from 22 sites in China were randomized between February 2012 and October 2015 to receive gemcitabine at 1 g/m² on days 1 and 8 and cisplatin at 80 mg/m² on day 1 (n = 181) or fluorouracil (5-FU) at 4 g/m² via continuous infusion over 96 hours and cisplatin on day 1 every 3 weeks, for a maximum of 6 cycles. The primary endpoint was progression-free survival on independent image committee assessment in the intent-to-treat population. The study is ongoing.

Progression-Free Survival

Median follow-up for progression-free survival was 19.4 months. Median progression-free survival was 7.0 months (95% confidence interval [CI] = 4.4–10.9 months) in the gemcitabine group vs 5.6 months (95% CI = 3.0–7.0 months) in the 5-FU group (hazard ratio [HR] = 0.55, P < .0001). Estimated progression-free survival was 66% vs 45% at 6 months, 20% vs 6% at 12 months, and 11% vs 2% at 18 months.

Objective response was observed in 64% vs 42 % (P < .0001), with complete response reported in 15 vs 5 patients; disease control rates were 90% vs 86%. Median follow-up for overall survival was 22.0 months. Median overall survival was 29.1 vs 20.9 months (HR = 0.62, P = .0025). After disease progression, 41% of the gemcitabine group and 48% of the 5-FU group received second- or third-line chemotherapy, with paclitaxel-containing salvage treatment being the most common.

Adverse Events

Treatment-related grade 3 or 4 adverse events significantly more common in the gemcitabine group were leukopenia (29% vs9%, P < .0001), neutropenia (23% vs 13%, P = .0251), and thrombocytopenia (13% vs 2%, P = .0007), with grade 3 or 4 mucosal inflammation being significantly more common in the 5-FU group (0% vs 14%, P < .0001). Serious treatment-related adverse events occurred in 4% vs 6%. Treatment-related adverse events led to discontinuation of treatment in 3% vs 8%. No treatment-related deaths were observed.

The investigators concluded: “Gemcitabine plus cisplatin prolongs progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma. The results establish gemcitabine plus cisplatin as the standard first-line treatment option for this population.”

The study was funded by the 5010 Clinical Research Foundation of Sun Yat-sen University.

Li Zhang, MD, of Sun Yat-sen University Cancer Center, is the corresponding author of The Lancet article.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.